This statistic shows the non-Hodgkin lymphoma death rate in the United States from 1999 to 2021. The maximum rate in the given period was 8.3 per 100,000 inhabitants in 1999. The minimum rate stood at 4.9 in 2021.

This statistic illustrates the number of deaths due to non-Hodgkin lymphoma cancer in the United States from 1999 to 2021. The highest number of deaths within the given period due to such lymphoma was reported in 1999, with over 22,800 deaths.

Market Overview:

The 7 major Burkitt lymphoma markets reached a value of US$ 996.4 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2,627.8 Million by 2034, exhibiting a growth rate (CAGR) of 9.22% during 2024-2034.

The Burkitt lymphoma market has been comprehensively analyzed in IMARC's new report titled "Burkitt Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Burkitt lymphoma refers to a type of non-Hodgkin lymphoma that is characterized by rapidly growing cancerous cells in the lymphatic system. Some of the common symptoms include swollen lymph nodes in the neck, armpit, or groin; fever; night sweats; weight loss; fatigue; abdominal pain or swelling, etc. In many cases, the cancer can affect other organs like the central nervous system or gastrointestinal tract, leading to additional symptoms, such as anemia, neurological problems, digestive issues, etc. The diagnosis of Burkitt lymphoma typically involves a combination of imaging procedures, blood tests, and a biopsy of an affected lymph node or other tissue. Various imaging studies, including CT scans and MRIs, can help identify the location and extent of the cancer, while blood tests may reveal abnormalities like anemia or elevated levels of lactate dehydrogenase (LDH). Additional tests, such as a bone marrow biopsy or lumbar puncture to look for cancer cells in the central nervous system, may be done to determine the subtype of Burkitt lymphoma and assess the extent of the disease.

https://www.imarcgroup.com/CKEditor/14c7d5be-1f67-48b7-9fdb-8a598255fe0aburkitt-lymphoma-market-report-(1).webp" style="height:450px; width:800px" />

The increasing incidences of genetic translocation, in which the MYC gene becomes overactive, thereby leading to uncontrolled cell growth and development of cancer, are primarily driving the Burkitt lymphoma market. In addition to this, the escalating utilization of stem cell transplantation in high-risk cases to help restore the immune system and prevent cancer recurrence, is further bolstering the market growth. Moreover, the widespread adoption of prophylactic CNS therapy, such as intrathecal chemotherapy or radiation therapy to the brain and spinal cord, for preventing or delaying CNS involvement is also creating a positive outlook for the Burkitt lymphoma market. Additionally, numerous key players are making extensive investments in developing reduced-intensity regimens that can achieve favorable outcomes with fewer side effects. This, in turn, is acting as another significant growth-inducing factor. Furthermore, the emerging popularity of molecular imaging techniques, such as positron emission tomography (PET) scans, since they can identify areas of disease that are not visible on conventional imaging, is expected to drive the Burkitt lymphoma market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the Burkitt lymphoma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Burkitt lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Burkitt lymphoma market in any manner.

Key Highlights:

• Endemic (African) Burkitt lymphoma (eBL) primarily affects the jaw and facial bone (orbit) (> 50% of cases).
• The incidence of Burkitt lymphoma in Africa is almost 50 times higher than in the U.S.
• Burkitt lymphoma is responsible for 30 to 50 percent of all childhood cancer in equatorial Africa, with an estimated frequency of 3 to 6 cases per 100,000 children each year.
• The peak incidence is observed in children aged four to seven years.
• Burkitt lymphoma has a male-to-female ratio of roughly 2:1.

Drugs:

Rituximab, also known as Rituxan, is a monoclonal antibody used to treat autoimmune disorders and cancers. It is administered via gradual intravenous infusion (slow injection through an IV line). Rituximab targets the protein CD20, which is predominantly located on the surface of immune system B cells. When it connects with this protein, it causes cell death.

Brexucabtagene autoleucel is an autologous chimeric antigen receptor (CAR) T cell therapy that uses a modified murine anti-CD19 single-chain variable fragment coupled to CD28 and CD3ζ co-stimulatory domains to treat Burkitt lymphoma.

PC-002 (also known as YM155 or sepantronium bromide) is a first-in-class small molecule inhibitor of DUBs, a family of enzymes that remove ubiquitin from cellular proteins that would otherwise be degraded. By blocking a crucial DUB activity that stabilizes the Myc protein in cancer cells, PC-002 selectively triggers Myc protein breakdown and cell death in Myc-dependent malignancies.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
  

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Burkitt lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Burkitt lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Burkitt lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Number of follicular lymphoma cases and trends in age-adjusted rates and relative frequency of FL among the incident NHL cases according to sex for the period 2008–2017.

Market Overview:

The 7 major small lymphocytic lymphoma markets are expected to exhibit a CAGR of 2.3% during 2024-2034.

The small lymphocytic lymphoma market has been comprehensively analyzed in IMARC's new report titled "Small Lymphocytic Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Small lymphocytic lymphoma refers to a type of non-Hodgkin lymphoma characterized by the abnormal proliferation of small mature B-lymphocytes in the lymph nodes and other organs. The condition can manifest with various symptoms, including painless swollen lymph nodes in the armpits, neck, or groin, unexplained fatigue, unintended weight loss, night sweats, recurrent infections, a feeling of fullness or discomfort in the abdomen, etc. The diagnosis of small lymphocytic lymphoma involves a combination of clinical evaluation, imaging studies, and pathological examination of lymph nodes or tissue biopsies. Initial assessment includes a thorough medical history, physical exam, and blood tests to evaluate the patient's overall health as well as detect any abnormalities. Various imaging techniques, such as computed tomography (CT) and positron emission tomography (PET) scans, are used to identify lymph node involvement and stage the disease. In order to confirm the diagnosis, a biopsy of an affected lymph node or other involved tissue is performed. Numerous additional tests, including flow cytometry, immunohistochemistry, genetic analysis, etc., are also conducted to determine specific markers and genetic alterations associated with the disease.

https://www.imarcgroup.com/CKEditor/961dddb7-59b7-405c-9fcb-a7b2251013casmall-lymphocytic-lymphoma-market.webp" style="height:450px; width:800px" />

The increasing prevalence of certain genetic abnormalities, which can disrupt normal cell growth and regulation, leading to the accumulation of abnormal B-cells, is primarily driving the small lymphocytic lymphoma market. In addition to this, the rising incidence of several associated risk factors, such as familial predisposition, advancing age, immunodeficiency conditions like human immunodeficiency virus (HIV) infection, etc., is acting as another significant growth-inducing factor. Moreover, the widespread adoption of immune checkpoint inhibitors, including pembrolizumab and nivolumab, that aid in enhancing the body's immune system to recognize and attack cancer cells more effectively is further bolstering the market growth. Apart from this, the escalating application of targeted therapy, which involves the use of drugs that selectively target specific molecules or pathways involved in cancer cell growth and survival, is also creating a positive outlook for the market. Additionally, the emerging popularity of circulating tumor DNA (ctDNA) analysis, since it helps in monitoring disease burden, assessing treatment response, and detecting the emergence of resistance mutations, is expected to drive the small lymphocytic lymphoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the small lymphocytic lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for small lymphocytic lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the small lymphocytic lymphoma market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2024-2034
  

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the small lymphocytic lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the small lymphocytic lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current small lymphocytic lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the small lymphocytic lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2034?
• What was the country-wise size of the small lymphocytic lymphoma market across the seven major markets in 2024 and what will it look like in 2034?
• What is the growth rate of the small lymphocytic lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
  

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of small lymphocytic lymphoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of small lymphocytic lymphoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of small lymphocytic lymphoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with small lymphocytic lymphoma across the seven major markets?
• What is the size of the small lymphocytic lymphoma patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of small lymphocytic lymphoma?
• What will be the growth rate of patients across the seven major markets?
  

Small Lymphocytic Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment

Non-Hodgkin Lymphoma Therapeutics Market Outlook

The global Non-Hodgkin Lymphoma (NHL) therapeutics market size was valued at approximately USD 7.8 billion in 2023 and is projected to reach USD 13.2 billion by 2032, growing at a compound annual growth rate (CAGR) of 5.8% during the forecast period. The market growth is primarily driven by advancements in targeted therapy and immunotherapy, alongside a growing prevalence of the disease worldwide.

One of the primary growth factors for the Non-Hodgkin Lymphoma therapeutics market is the increasing incidence of NHL globally. As per the World Health Organization (WHO), around 500,000 new cases of NHL are diagnosed each year. This rising prevalence necessitates effective therapeutic solutions, thereby driving market growth. Additionally, an aging global population, which is more susceptible to such diseases, further fuels the demand for advanced treatment options. Innovations in medical technology, including next-generation sequencing, have also played a crucial role in the early detection and treatment of NHL, thereby positively impacting the market.

Another significant growth factor is the advancement in immunotherapy and targeted therapy. These therapies have shown a higher efficacy rate and reduced side effects compared to traditional chemotherapy. Major pharmaceutical companies are investing heavily in the research and development of novel therapeutic options, such as CAR T-cell therapy and monoclonal antibodies, which are proving to be game-changers in the treatment landscape. The U.S. Food and Drug Administration (FDA) and other regulatory bodies have expedited the approval processes for these advanced therapeutics, which further accelerates market growth.

Government initiatives and increased healthcare expenditure are also major contributing factors to the market's expansion. Various governments and health organizations are implementing programs to raise awareness about early diagnosis and effective treatment options for NHL. These initiatives not only enhance the quality of care but also make advanced treatments more accessible, particularly in developing countries. Furthermore, the availability of healthcare insurance is improving treatment affordability, making it easier for patients to opt for advanced therapies.

Mantle Cell Lymphoma Therapeutics have emerged as a critical area of focus within the broader Non-Hodgkin Lymphoma treatment landscape. As a rare and aggressive form of NHL, Mantle Cell Lymphoma poses unique challenges that necessitate specialized therapeutic approaches. Recent advancements in targeted therapies and immunotherapies have shown promise in improving patient outcomes. For instance, the development of Bruton’s tyrosine kinase inhibitors and proteasome inhibitors has provided new avenues for treatment, offering hope for patients who previously had limited options. The integration of these novel therapies into clinical practice is gradually transforming the management of Mantle Cell Lymphoma, highlighting the importance of continued research and innovation in this field.

Regionally, North America holds the largest share of the Non-Hodgkin Lymphoma therapeutics market, followed by Europe and the Asia Pacific. The United States, in particular, is a significant contributor, driven by high healthcare expenditure, advanced medical infrastructure, and a robust pipeline of innovative therapies. Europe follows closely, with countries like Germany, France, and the UK leading in terms of market size and growth. The Asia Pacific region is anticipated to show the highest CAGR during the forecast period, driven by increasing healthcare investments, improving healthcare infrastructure, and a rising patient population.

Treatment Type Analysis

The chemotherapy segment has traditionally been the cornerstone of Non-Hodgkin Lymphoma treatment. Despite the advent of newer therapies, chemotherapy remains a widely used treatment option due to its efficacy in reducing tumor size and eliminating cancer cells. However, its side effects, such as hair loss, nausea, and immunosuppression, have led to a decline in its preference among patients who have access to more advanced therapeutic options. Nevertheless, chemotherapy is still a standard treatment, particularly in regions with limited access to advanced medical technology.

The global market size of Lymphoma Therapeutics is $XX million in 2018 with XX CAGR from 2014 to 2018, and it is expected to reach $XX million by the end of 2024 with a CAGR of XX% from 2019 to 2024.
Global Lymphoma Therapeutics Market Report 2019 - Market Size, Share, Price, Trend and Forecast is a professional and in-depth study on the current state of the global Lymphoma Therapeutics industry. The key insights of the report:
1.The report provides key statistics on the market status of the Lymphoma Therapeutics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.
2.The report provides a basic overview of the industry including its definition, applications and manufacturing technology.
3.The report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for key vendors.
4.The total market is further divided by company, by country, and by application/type for the competitive landscape analysis.
5.The report estimates 2019-2024 market development trends of Lymphoma Therapeutics industry.
6.Analysis of upstream raw materials, downstream demand, and current market dynamics is also carried out
7.The report makes some important proposals for a new project of Lymphoma Therapeutics Industry before evaluating its feasibility.
There are 4 key segments covered in this report: competitor segment, product type segment, end use/application segment and geography segment.
For competitor segment, the report includes global key players of Lymphoma Therapeutics as well as some small players. At least 11 companies are included:
* F. Hoffmann-La Roche AG
* Eli Lilly
* Pfizer Inc.
* Bristol-Myers Squibb (BMS)
* Celgene Corp.
* GlaxoSmithKline
For complete companies list, please ask for sample pages.
The information for each competitor includes:
* Company Profile
* Main Business Information
* SWOT Analysis
* Sales, Revenue, Price and Gross Margin
* Market Share

For product type segment, this report listed main product type of Lymphoma Therapeutics market
* Product Type I
* Product Type II
* Product Type III

For end use/application segment, this report focuses on the status and outlook for key applications. End users sre also listed.
* Hodgkin Lymphoma
* Non-Hodgkin Lymphoma

For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented from 2013 to 2023. This report covers following regions:
* North America
* South America
* Asia & Pacific
* Europe
* MEA (Middle East and Africa)
The key countries in each region are taken into consideration as well, such as United States, China, Japan, India, Korea, ASEAN, Germany, France, UK, Italy, Spain, CIS, and Brazil etc.

Reasons to Purchase this Report:
* Analyzing the outlook of the market with the recent trends and SWOT analysis
* Market dynamics scenario, along with growth opportunities of the market in the years to come
* Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects
* Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
* Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
* Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
* Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
* 1-year analyst support, along with the data support in excel format.
We also can offer customized report to fulfill special requirements of our clients. Regional and Countries report can be provided as well.

Market Overview:

The 7 major primary gastric lymphoma markets reached a value of US$ 1.9 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 8.1 Billion by 2034, exhibiting a growth rate (CAGR) of 14.03% during 2024-2034.

The primary gastric lymphoma market has been comprehensively analyzed in IMARC's new report titled "Primary Gastric Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Primary gastric lymphoma (PGL) is a rare type of non-Hodgkin lymphoma that originates in the stomach's lymphatic tissue. The symptoms of this ailment can be vague and may mimic those of other gastrointestinal disorders, making diagnosis challenging. Individuals suffering from the illness might experience abdominal discomfort, pain, bloating, early satiety, unexplained weight loss, nausea, vomiting, etc. Due to its nonspecific presentation, timely recognition of PGL is crucial. The diagnosis of lymphoma involves a combination of methods. Endoscopy with biopsy is a pivotal step, allowing for the collection of tissue samples for microscopic examination. This investigation aids in identifying lymphoma cells and determining their specific subtype. Physicians might also recommend imaging studies, such as CT scans or MRIs, to assess the extent of the disease and exclude the involvement of various other organs. Numerous diagnostic tests, like blood work, including complete blood counts and molecular analysis, can also be utilized in patients.

https://www.imarcgroup.com/CKEditor/a9d19168-ae70-4908-80e5-8148155f3b92primary-gastric-lymphoma-market.webp" style="height:450px; width:800px" />

The escalating incidences of gene mutations, leading to abnormal growth of lymphatic cells within the stomach lining, are primarily driving the primary gastric lymphoma market. In addition to this, the inflating utilization of effective treatments, such as chemotherapy regimens, radiotherapy, immunotherapy, and surgery, aimed at managing the disease and preventing its progression, is also creating a positive outlook for the market. Moreover, the widespread adoption of targeted therapies, since they help in leveraging drugs that specifically pinpoint certain molecules involved in the proliferation and survival of lymphoma cells, is further bolstering the market growth. Apart from this, the rising usage of endoscopic procedures, which enable minimally invasive diagnosis and treatment by directly visualizing and accessing the affected area, is acting as another significant growth-inducing factor. These techniques facilitate accurate staging of the ailment as well as offer a platform for biopsy and subsequent therapeutic interventions. Additionally, the growing awareness of complementary approaches like nutritional support and integrative therapies that can enhance the overall well-being of patients who are undergoing treatment is also augmenting the market growth. Furthermore, the emergent application of personalized medicine strategies, which hold the potential to optimize treatment outcomes and minimize adverse effects, is expected to drive the primary gastric lymphoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the primary gastric lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for primary gastric lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the primary gastric lymphoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
  

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the primary gastric lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the primary gastric lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current primary gastric lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the primary gastric lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the primary gastric lymphoma market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the primary gastric lymphoma market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
  

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of primary gastric lymphoma across the seven major markets?
• What is the number of prevalent cases (2018-2034) of primary gastric lymphoma by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of primary gastric lymphoma by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with primary gastric lymphoma across the seven major markets?
• What is the size of the primary gastric lymphoma patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of primary gastric lymphoma?
• What will be the growth rate of patients across the seven major markets?
  

Primary Gastric Lymphoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for primary gastric lymphoma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the primary gastric lymphoma market?
• What are the key regulatory events related to the primary gastric lymphoma market?
• What is the structure of clinical trial landscape by status related to the primary gastric lymphoma market?
• What is the structure of clinical trial landscape by phase related

The global intraocular lymphoma treatment market is slated to reach a valuation of US$ 1.2 billion by the end of 2023. According to Future Market Insights, the market is projected to rise at a 6.7% CAGR until 2033, being valued at US$ 2.3 billion. Intraocular lymphomas are rare malignancies, showing a wide spectrum of clinical manifestations. Therefore, its diagnosis appears to be highly challenging.

Report Scope

Snapshot img

Car T-Cell Therapy Market Size 2025-2029

The car t-cell therapy market size is forecast to increase by USD 3.56 billion at a CAGR of 17.3% between 2024 and 2029. The market is witnessing substantial growth due to several key factors. Firstly, growing awareness regarding Car T-Cell Therapy is driving demand for this innovative treatment option. Secondly, the increasing prevalence of blood cancer and hematological malignancies is fueling the need for advanced solutions. These conditions affect a significant number of individuals, making the development of effective treatments a priority. Moreover, advancements in technology are enabling more efficient systems and better accessibility, making Car T-Cell Therapy more accessible to a larger patient population. Additionally, industry standards continue to evolve, with a focus on sustainability and operational efficiency. Companies In the market are responding to these trends by adjusting their strategies to meet the growing demand for advanced solutions. They are prioritizing research and development to bring new and innovative products to market, while also focusing on operational efficiency and cost-effectiveness.

What will be the size of the market during the forecast period?

Request Free Sample

Car T-Cell Therapy Market Segmentation

The car t-cell therapy market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019 - 2023 for the following segments.

End-user

  Hospitals
  Cancer treatment centers


Type

  CD19
  CD22
  BCMA
  Others


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

Which is the largest segment driving market growth?

The hospitals segment is estimated to witness significant growth during the forecast period.

CAR T-cell therapy, a type of cell-based immunotherapy, is gaining significant traction In the treatment of various cancers, including leukemia and lymphoma. The global market for this innovative therapy is primarily driven by the increasing incidence of cancer, reimbursement policies, and public awareness. Hospitals, as key end-users, hold the largest share of this market due to their role in administering and managing these complex treatments. They provide the necessary infrastructure, medical staff, and resources for CAR T-cell therapy. Hematologic malignancies, such as leukemia and non-Hodgkin lymphoma, are the primary indications for CAR T-cell therapy. Companies like Juno Therapeutics, Tessa Therapeutics, Adaptimmune, and Celgene Corporation are leading the innovation in this field.

Scalability, cost-effectiveness, product consistency, and quality control measures are crucial for the success of CAR T-cell therapies. The use of genetic modification and precision medicine in cancer treatment is expected to further fuel market growth. Despite the potential benefits, systemic toxicity remains a concern. Clinical trials and financial backing are essential for the development and approval of new CAR T-cell therapies.

Get a glance at the market share of various regions. Download the PDF Sample

The Hospitals segment was valued at USD 958.30 million in 2019 and showed a gradual increase during the forecast period.

Which region is leading the market?

North America is estimated to contribute 41% to the growth of the global market during the forecast period.

For more insights on the market share of various regions, Request Free Sample

Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.The market in North America is expected to dominate due to the high incidence of cancer and the presence of advanced healthcare infrastructure. With an estimated 1.9 million new cancer cases In the US in 2023 (American Cancer Society 2023 Cancer Statistics), the demand for innovative cancer treatments, such as CAR T-cell therapy, is increasing. This market is driven by significant investments in research and development, reimbursement policies, and patient-centric approaches. Key players, including Gilead Sciences, Inc., are based in North America, contributing to the region's market growth. CAR T-cell therapies, which use genetically modified T-cells to target and destroy cancer cells, are revolutionizing the treatment landscape for hematologic malignancies, including leukemia and non-Hodgkin lymphoma.

Innovations, such as CRISPR/Cas9 gene editing technology and scalable manufacturing processes, are enhancing the cost-effectiveness and product consistency of these therapies. Clinical trials for solid tumors, including ovarian cancer, are also underway, expanding the application of CAR T-cell therapies beyond blood cancers.

BackgroundNon-Hodgkin lymphomas are a heterogeneous group of solid tumours that constitute the 5th highest cause of cancer mortality in the United States and Canada. Poor control of cell death in lymphocytes can lead to autoimmune disease or cancer, making genes involved in programmed cell death of lymphocytes logical candidate genes for lymphoma susceptibility. Materials and MethodsWe tested for genetic association with NHL and NHL subtypes, of SNPs in lymphocyte cell death genes using an established population-based study. 17 candidate genes were chosen based on biological function, with 123 SNPs tested. These included tagSNPs from HapMap and novel SNPs discovered by re-sequencing 47 cases in genes for which SNP representation was judged to be low. The main analysis, which estimated odds ratios by fitting data to an additive logistic regression model, used European ancestry samples that passed quality control measures (569 cases and 547 controls). A two-tiered approach for multiple testing correction was used: correction for number of tests within each gene by permutation-based methodology, followed by correction for the number of genes tested using the false discovery rate. ResultsVariant rs928883, near miR-155, showed an association (OR per A-allele: 2.80 [95% CI: 1.63–4.82]; pF = 0.027) with marginal zone lymphoma that is significant after correction for multiple testing. ConclusionsThis is the first reported association between a germline polymorphism at a miRNA locus and lymphoma.

Market Overview:

The 7 major follicular lymphoma markets reached a value of US$ 1.6 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.2 Billion by 2034, exhibiting a growth rate (CAGR) of 3.16% during 2024-2034.

The follicular lymphoma market has been comprehensively analyzed in IMARC's new report titled "Follicular Lymphoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Follicular lymphoma is the most common type of low-grade non-Hodgkin's lymphoma, in which white blood cells gather to form masses in the lymph nodes or other organs. The white blood cells, also known as lymphocytes, are fundamental to the immune system and help the body fight infections. Follicular lymphoma is graded 1–3 (low to high grade) based on histology. Some of the common symptoms of the ailment include swollen lymph nodes, which may be painless or tender to the touch, fatigue, unexplained weight loss, night sweats, and fever. A few patients may also experience abdominal pain, bloating, or constipation if the lymphoma affects the abdominal area. In its advanced stages, the disease can cause bone pain, anemia, and increased susceptibility to infections. The diagnosis of this condition usually requires a combination of medical history, laboratory studies, and a physical examination. Numerous other tests, such as positron emission tomography (PET) scan, computed tomography (CT) scan, and magnetic resonance imaging (MRI), along with lymph node morphological assessment and flow cytometry, are utilized to confirm a diagnosis. Additionally, the healthcare professional may perform a bone marrow biopsy to validate the disease staging among patients.

https://www.imarcgroup.com/CKEditor/3cd01a59-9780-488a-beb6-984194600aeefollicular-lymphoma-market.jpg" style="height:450px; width:800px" />

The increasing cases of autoimmune disorders, such as rheumatoid arthritis, lupus, celiac disease, etc., resulting in an overactive immune system, are primarily driving the follicular lymphoma market. Apart from this, the rising prevalence of various associated risk factors, including age-related issues, weakened immune system, exposure to certain chemicals, etc., is further bolstering the market growth. Moreover, the widespread adoption of monoclonal antibodies to kill lymphoma cells without harming healthy body tissues is creating a positive outlook for the market. Besides this, the inflating usage of whole-body combined fluorodeoxyglucose (FDG) PET with CT for diagnosing the ailment on account of its numerous advantages, such as a more detailed examination of the structures, cells, and functioning of body tissues with improved specificity and tumor sensitivity, is also augmenting the market growth. Furthermore, several key players are making extensive investments in the development of targeted therapies, including drugs that target the CD20 protein on B-cells, for tackling specific molecules or pathways involved in the growth and survival of cancer cells. This, in turn, is acting as another significant growth-inducing factor. Additionally, the escalating demand for chimeric antigen receptor (CAR) T cell therapy, which can enhance, modify, and activate T cells to identify and destroy the tumor, is expected to drive the follicular lymphoma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the follicular lymphoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for follicular lymphoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the follicular lymphoma market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the follicular lymphoma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the follicular lymphoma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current follicular lymphoma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the follicular lymphoma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
<li

Median (IQR) monthly costs (USD), under the base case, and for each of the sensitivity and subgroup analysis scenarios.

Market Overview:

The 7 major mycosis fungoides markets are expected to exhibit a CAGR of 4.9% during 2024-2034.

The mycosis fungoides market has been comprehensively analyzed in IMARC's new report titled "Mycosis Fungoides Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Mycosis fungoides refers to a rare type of non-Hodgkin lymphoma that primarily affects the skin. It is categorized as a form of cutaneous T-cell lymphoma, arising from malignant T-cells in the skin's outer layer. This disease often presents challenges in diagnosis due to its variable and insidious nature. The symptoms of mycosis fungoides typically manifest in stages, with the initial phase resembling eczema-like skin changes, such as redness, itching, and sometimes raised patches. As the disease progresses, more pronounced indications like thickened, scaly, or ulcerated skin patches, tumors, and lymph node enlargement can occur. In advanced cases, the lymphoma may spread to various other organs. Diagnosing mycosis fungoides involves a combination of clinical evaluation, skin biopsies, and several laboratory tests. Dermatologists and oncologists analyze the skin's appearance, texture, and symptoms while also conducting biopsies to examine the presence of abnormal T-cells. Advanced techniques, like immunophenotyping and molecular studies might be conducted for definitive confirmation.

https://www.imarcgroup.com/CKEditor/417bbfbe-42e5-4c4b-b7b7-b8bbba58e274mycosis-fungoides-market.webp" style="height:450px; width:800px" />

The increasing incidences of immune system dysfunction, causing the buildup of malignant white blood cells in the skin, are primarily driving the mycosis fungoides market. In addition to this, the inflating utilization of efficacious therapeutics, such as methotrexate, interferons, and retinoids, is also creating a positive outlook for the market. These medications are pivotal in managing symptoms, slowing disease progression, and alleviating discomfort, thereby enhancing the quality of life for patients. Moreover, the widespread adoption of phototherapy, since it involves the application of ultraviolet light to target affected skin cells, is further bolstering the market growth. Apart from this, the rising usage of radiation therapy, particularly for localized plaques and tumors, due to its effectiveness in reducing the proliferation of cancerous cells with minimal systemic side effects, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive care measures, such as topical corticosteroids and emollients, to alleviate symptoms like itchiness, redness, and discomfort in patients is also augmenting the market growth. Furthermore, the escalating demand for innovative treatment modalities, including extracorporeal photopheresis, which involves the removal, treatment, and reinfusion of a patient's blood to stimulate immune responses against cancerous cells, is expected to drive the mycosis fungoides market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the mycosis fungoides market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for mycosis fungoides and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the mycosis fungoides market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
  

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the mycosis fungoides market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the mycosis fungoides market
• Reimbursement scenario in the market
• In-market and pipeline drugs
  

Competitive Landscape

This report also provides a detailed analysis of the current mycosis fungoides marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
  

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report

Market Insights

• How has the mycosis fungoides market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the mycosis fungoides market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the mycosis fungoides market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
  

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of mycosis fungoides across the seven major markets?
• What is the number of prevalent cases (2018-2034) of mycosis fungoides by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of mycosis fungoides by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with mycosis fungoides across the seven major markets?
• What is the size of the mycosis fungoides patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of mycosis fungoides?
• What will be the growth rate of patients across the seven major markets?
  

Mycosis Fungoides: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they

According to a ranking of the best hospitals in the U.S., the best hospital for adult cancer is the University of Texas MD Anderson Cancer Center, which had a score of 100 out of 100, as of 2024. This statistic shows the top 10 hospitals for adult cancer in the United States based on the score given by U.S. News and World Report's annual hospital ranking.

Snapshot img

Anti-CD20 Monoclonal Antibodies Market Size 2025-2029

The anti-CD20 monoclonal antibodies (MABs) market size is forecast to increase by USD 15.64 billion at a CAGR of 12.3% between 2024 and 2029.

The market is experiencing significant growth due to the increasing use of combination therapies In the treatment of various diseases. These mAbs, which target the CD20 protein found on the surface of B cells, are increasingly being used in immunology and inflammatory bowel disease therapies. The market is driven by the rising awareness of therapeutic areas and the potential benefits of mAb treatments. However, the market also faces challenges, including the adverse effects associated with anti-CD20 mAbs, such as infusion reactions and the risk of developing neutralizing antibodies. These factors may limit the market growth and require ongoing research and development efforts to mitigate their impact. Ambulatory surgical centers and blood banks are key institutions where the demand for anti-CD20 mAbs is increasing due to the convenience and cost-effectiveness of outpatient treatments. Overall, the market for anti-CD20 mAbs is expected to continue growing, driven by the increasing demand for targeted therapies and ongoing research and development efforts to address the challenges associated with their use.

What will be the Size of the market During the Forecast Period?

Request Free Sample

The market encompasses a range of immunotherapeutic agents used primarily in the treatment of B-cell malignancies and certain autoimmune diseases. These mAbs target the CD20 marker found on the surface of mature and malignant B cells, as well as macrophages. The market's growth is driven by the increasing prevalence of B-cell malignancies, such as lymphoma, and autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and multiple sclerosis. The prognosis for patients with these conditions has significantly improved due to the efficacy of anti-CD20 mAbs, leading to increased demand.


In the realm of oncology, anti-CD20 mAbs are utilized extensively In the neuroscience and immunology sectors. Notable anti-CD20 mAbs include ofatumumab and ocrelizumab. The market is expected to continue expanding due to the ongoing research and development efforts In the immunotherapy space.

How is this market segmented and which is the largest segment?

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Product

  Oncology
  Neurology
  Immunology


Type

  First generation
  Second generation
  Third generation


End-user

  Hospitals and clinics
  Academic and research institutions
  Contract research organizations


Drug Class

  Rituximab
  Ofatumumab
  Obinutuzumab
  Ublituximab
  Others


Route Of Administration

  Intravenous
  Subcutaneous


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  Asia
  Rest of World (ROW)

By Product Insights

The oncology segment is estimated to witness significant growth during the forecast period. The market is primarily driven by the oncology segment due to the approval of these mAbs for treating prevalent cancer indications. Four out of five anti-CD20 mAbs are authorized for various cancer types, including non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and follicular lymphoma. The high incidence and prevalence of cancer, with an estimated 20 million new cases and 9.7 million deaths in 2022 (NCI), are expected to fuel market growth. Anti-CD20 mAbs target mature and malignant B cells, macrophages, and autoimmune disorders. These mAbs are used in immunotherapy for treating B-cell malignancies and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and multiple sclerosis.

Get a glance at the market report of share of various segments Request Free Sample

Market Dynamics

Our Anti-Cd20 Monoclonal Antibodies (Mabs) Market researchers analyzed the data with 2024 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.

What are the key market drivers leading to the rise in adoption of Anti-CD20 Monoclonal Antibodies (Mabs) Market?

Increased use of combination therapies is the key driver of the market. The market is experiencing substantial growth due to the increasing utilization of combination therapies for treating various indications. Anti-CD20 mABs are the preferred choice for targeted therapy in CD20 antigen-expressing diseases across therapeutic areas like oncology, immunology, and neurology. Combination th

In 2020, both the estimated U.S. net price and gross price for a one-month supply (90 capsules) of Imbruvica Oral Capsule (140mg) were roughly two times higher than gross prices paid in the comparison countries. Imbruvica is a cancer medicine used to treat chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's Macroglobulinemia. This statistic shows Imbruvica's net and gross prices in the United States compared to gross prices in Australia, Canada, and France as of 2020.